SCHEMBL1436058

SCHEMBL1436058

Cc1cc(-c2cccnc2)n[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 2/20 1.00
CYP3A4 P08684 3/20 0.69
ALDH1A1 P00352 2/20 0.69
CYP1A2 P05177 2/20 0.69
L3MBTL1 Q9Y468 1/20 0.65
CYP2A6 P11509 6/20 0.64
CYP2C9 P11712 2/20 0.64
CYP2B6 P20813 2/20 0.64
CYP2C19 P33261 2/20 0.64
CYP2D6 P10635 1/20 0.64
PIM1 P11309 5/20 0.57
PIM3 Q86V86 2/20 0.57
PIM2 Q9P1W9 2/20 0.57
CHEK1 O14757 1/20 0.53
AURKA O14965 1/20 0.53
DAPK3 O43293 1/20 0.53
JAK2 O60674 1/20 0.53
PRKD3 O94806 1/20 0.53
MAP4K4 O95819 1/20 0.53
PAK4 O96013 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7236291 0.81 CYP2A6 (0.72) ALKCYP3A4ALDH1A1CYP1A2CYP2A6
SCHEMBL3078162 0.80 CYP3A4 (0.89) ALKCYP3A4ALDH1A1CYP1A2CYP2A6
SCHEMBL23546380 0.79 CYP2A6 (0.68) ALKCYP3A4ALDH1A1CYP1A2CYP2A6
SCHEMBL427627 0.79 L3MBTL1 (1.00) ALKCYP1A2L3MBTL1CYP2C9CYP2C19
SCHEMBL1364633 0.79 ALDH1A1 (0.69) ALKCYP3A4ALDH1A1CYP1A2CYP2A6
SCHEMBL12056298 0.79 ALDH1A1 (0.69) ALKCYP3A4ALDH1A1CYP1A2CYP2A6
SCHEMBL29633361 0.79 ALDH1A1 (0.69) ALKCYP3A4ALDH1A1CYP1A2CYP2A6
SCHEMBL7241501 0.78 ALK (0.64) ALKCYP3A4ALDH1A1CYP1A2CYP2A6
SCHEMBL28154455 0.78 CYP2A6 (0.72) ALKCYP3A4ALDH1A1CYP1A2CYP2A6
SCHEMBL3608558 0.78 CYP2A6 (1.00) ALKCYP3A4ALDH1A1CYP1A2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021183439-A1 SUBSTITUTED FURO[3,2-D]PYRIMIDINES AND USES THEREOF Verge Analytics, Inc. (US) 2021-09-16 WO disclosed
WO-2012000519-A1 ARYL- AND HETEROARYLAMID DERIVATIVES AS PDE10A ENZYME INHIBITOR H. LUNDBECK A/S (DK) 2012-01-05 WO disclosed
EP-1441719-B1 N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS HOFFMANN LA ROCHE (CH) 2011-03-30 EP disclosed
US-7803819-B2 DPP IV inhibitors HOFFMANN-LA ROCHE INC. (US) 2010-09-28 US disclosed
US-7314884-B2 non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile HOFFMANN-LA ROCHE INC. (US) 2008-01-01 US disclosed
US-20070259925-A1 DPP IV INHIBITORS BOEHRINGER MARKUS 2007-11-08 US disclosed
EP-1706396-A1 N-(4-CARBAMIMIDOYL-BENZYL)-2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA F.HOFFMANN-LA ROCHE AG (CH) 2006-10-04 EP disclosed
WO-2005058868-A1 N-(4-CARBAMIMIDOYL-BENZYL) -2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050096348-A1 DPP IV inhibitors BOEHRINGER MARKUS (CH) 2005-05-05 US disclosed
US-6861440-B2 DPP IV inhibitors HOFFMANN-LA ROCHE INC. (US) 2005-03-01 US disclosed
EP-1441719-A1 N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-04 EP disclosed
US-20030130281-A1 DPP IV inhibitors HOFFMAN-LA ROCHE INC. 2003-07-10 US disclosed
WO-2003037327-A1 N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS F. HOFFMANN-LA-ROCHE AG (CH) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259925-A1 DPP IV INHIBITORS DPP4, DPP3, DPP7 ALK 2579/4885CYP3A4 82/4885ALDH1A1 233/4885
US-20030130281-A1 DPP IV inhibitors DPP4, DPP3, DPP7 ALK 3332/4885CYP3A4 171/4885ALDH1A1 133/4885
US-20050096348-A1 DPP IV inhibitors DPP4, DPP3, DPP7 ALK 2579/4885CYP3A4 82/4885ALDH1A1 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.